Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
01:58:53 EDT Wed 10 Jun 2026
Enter Symbol
or Name
USA
CA



Forgot password?
Trouble logging in?
Login ID:
Password:
Save

News for U:INCY from 2025-06-11 to 2026-06-10 - 73 items News ReleasesIn The NewsOther CAUS
DateSymPriceTypeHeadline
2026-06-08 07:00U:INCYNews ReleaseIncyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
2026-06-04 08:05U:INCYNews ReleaseMirum Pharmaceuticals and Incyte Announce Pivotal Late-Breaking Results for Zilurgisertib in Fibrodysplasia Ossificans Progressiva Accepted for Presentation at ENDO 2026
2026-05-30 08:00U:INCYNews ReleaseIncyte's Pivotal frontMIND Trial Showed Tafasitamab (Monjuvi(TM)/Minjuvi(TM)) Combination Significantly Prolonged Progression-free Survival, Reducing the Risk of Disease Progression or Death by 25% in Patients with Previously Untreated, High-risk DLBCL
2026-05-26 08:00U:INCYNews ReleaseIncyte to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
2026-05-20 08:00U:INCYNews ReleaseIncyte and Genesis Expand Molecular AI Collaboration to Accelerate Drug Discovery
2026-05-19 08:00U:INCYNews ReleaseIncyte and Edison Scientific Announce Strategic Collaboration to Employ the Kosmos AI Platform for Research and Development
2026-05-12 09:30U:INCYNews ReleaseIncyte Announces More Than 20 Abstracts Accepted for Presentation at the European Hematology Association (EHA) 2026 Congress
2026-05-06 16:30U:INCYNews ReleaseIncyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-05-01 17:28U:INCYNews ReleaseIncyte Announces FDA Approval of Jakafi XR(TM) (ruxolitinib) Extended-Release Tablets for the Treatment of Myelofibrosis, Polycythemia Vera and Graft-Versus-Host Disease
2026-04-29 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2026-04-28 07:00U:INCYNews ReleaseIncyte Appoints Suketu (Suky) Upadhyay as Chief Financial Officer
2026-04-28 07:00U:INCYNews ReleaseIncyte Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-04-21 10:00U:INCYNews ReleaseIncyte Highlights New Phase 3 Tafasitamab Data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
2026-04-09 08:00U:INCYNews ReleaseIncyte to Report First Quarter Financial Results
2026-04-07 07:30U:INCYNews ReleasePalvella Therapeutics Appoints Accomplished Commercial Leader Kent Taylor as Senior Vice President of Sales
2026-04-02 07:01U:INCYNews ReleaseAdagene Announces Clinical Collaboration with Incyte to Evaluate Muzastotug (ADG126) in Combination with Incyte's TGFsR2xPD-1 Bispecific Antibody (INCA33890) in Patients with Microsatellite Stable Colorectal Cancer (MSS CRC)
2026-03-28 15:00U:INCYNews ReleaseIncyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting
2026-03-25 09:00U:INCYNews ReleaseIncyte Announces Executive Leadership Appointments
2026-03-20 10:00U:INCYNews ReleaseIncyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting
2026-03-17 07:30U:INCYNews ReleaseKnight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI(TM) (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
2026-03-17 07:30U:INCYNews ReleaseKnight Therapeutics Announces Approval of Additional Indication for MINJUVI(TM) (tafasitamab) in Brazil
2026-03-06 16:42U:INCYNews ReleaseIncyte Announces the European Commission Approval of Zynyz(TM) (retifanlimab) for the First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)
2026-02-27 08:11U:INCYNews ReleaseLilly's Olumiant (baricitinib) recommended by CHMP for approval of expanded use in the European Union for adolescents with severe alopecia areata
2026-02-17 10:48U:INCYNews ReleaseRegistration Momentum Builds Across the Oncology Pipeline
2026-02-17 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2026-02-10 07:00U:INCYNews ReleaseIncyte Reports Fourth Quarter and Full Year 2025 Financial Results
2026-01-27 08:00U:INCYNews ReleaseIncyte to Report Fourth Quarter and Year-End 2025 Financial Results
2026-01-05 07:30U:INCYNews ReleaseIncyte Announces Positive Topline Results from Pivotal Study of Tafasitamab (Monjuvi(TM)/Minjuvi(TM)) as a First-line Treatment for Diffuse Large B-Cell Lymphoma
2025-12-22 02:44U:INCYNews ReleaseIncyte Japan Announces Approval of Minjuvi(TM) (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma
2025-12-22 02:42U:INCYNews ReleaseIncyte Japan Announces Approval of Zynyz(TM) (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer
2025-12-18 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conference
2025-12-17 11:20U:INCYNews ReleaseIncyte Announces European Commission Approval of Minjuvi(TM) (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma
2025-12-12 08:30U:INCYNews ReleaseIncyte Announces Change to its Board of Directors
2025-12-08 16:30U:INCYNews ReleaseIncyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia
2025-12-07 09:30U:INCYNews ReleaseIncyte's First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA
2025-12-07 09:30U:INCYNews ReleaseIncyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025
2025-12-03 16:30U:INCYNews ReleaseIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-12-02 09:15U:INCYNews ReleaseIncyte and Winnie Harlow Join Forces to Share Her Personal Vitiligo Story and Spark Conversation and Understanding
2025-12-01 08:00U:INCYNews ReleaseIncyte Appoints Richard Hoffman as Executive Vice President and General Counsel
2025-11-19 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2025-11-06 09:15U:INCYNews ReleaseIncyte's Moments of Clarity Program Expands to Highlight Powerful Patient Stories in Vitiligo and Pediatric Eczema
2025-11-04 07:01U:INCYNews ReleasePrelude Therapeutics Announces Exclusive Option Agreement with Incyte to Advance Mutant Selective JAK2V617F JH2 Inhibitors
2025-11-03 09:31U:INCYNews ReleaseIncyte Announces More than 50 Abstracts Accepted for Presentation at the 2025 ASH Annual Meeting
2025-10-30 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2025-10-28 07:00U:INCYNews ReleaseIncyte Reports Third Quarter 2025 Financial Results and Provides Business Updates
2025-10-27 07:30U:INCYNews ReleaseIncyte and Enable Injections Announce Strategic Partnership for enFuse(TM) On-Body Delivery System
2025-10-25 19:55U:INCYNews ReleaseIncyte Announces New Data from Phase 3b TRuE-AD4 Trial of Opzelura(TM) (Ruxolitinib Cream) in Adults with Moderate Atopic Dermatitis
2025-10-24 06:45U:INCYNews ReleaseLilly's baricitinib delivered near-complete scalp hair regrowth at one year for adolescents with severe alopecia areata in Phase 3 BRAVE-AA-PEDS trial
2025-10-19 13:30U:INCYNews ReleaseIncyte Announces Phase 1 Results for its TGFbetaR2*PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma
2025-10-12 18:05U:INCYNews ReleaseData from Incyte's TGFbetaR2*PD-1 Bispecific Antibody and KRAS G12D Inhibitor to be Presented at the European Society of Medical Oncology (ESMO) Congress 2025
2025-10-08 08:00U:INCYNews ReleaseIncyte to Report Third Quarter Financial Results
2025-09-24 16:30U:INCYNews ReleaseIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-09-22 07:30U:INCYNews ReleaseIncyte Announces the Appointment of Dave Gardner as Executive Vice President and Chief Strategy Officer
2025-09-18 16:21U:INCYNews ReleaseIncyte Announces Additional FDA Approval of Opzelura(TM) (Ruxolitinib) Cream in Children Ages 2-11 with Atopic Dermatitis
2025-09-17 01:00U:INCYNews ReleaseIncyte Announces New 24-Week Phase 3 Data from the STOP-HS Clinical Trial Program of Povorcitinib in Hidradenitis Suppurativa at EADV 2025
2025-09-10 07:30U:INCYNews ReleaseIncyte to Present New Data Highlighting Progress Across its Dermatology Pipeline at the European Association of Dermatology and Venerology 2025 Congress
2025-09-03 09:15U:INCYNews ReleaseIncyte Launches HS TRUTHS to Spotlight the True Lived Experience of Hidradenitis Suppurativa
2025-08-27 16:15U:INCYNews ReleaseIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-08-25 08:00U:INCYNews ReleaseIncyte Announces the Appointment of Soni Basi as Executive Vice President and Chief Human Resources Officer
2025-08-19 08:00U:INCYNews ReleaseIncyte to Present at Upcoming Investor Conferences
2025-08-05 16:05U:INCYNews ReleaseIncyte Announces Departure of Chief Financial Officer Christiana Stamoulis
2025-08-04 16:30U:INCYNews ReleaseKnight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
2025-07-31 16:30U:INCYNews ReleaseKnight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI(TM) (tafasitamab) for Follicular Lymphoma in Brazil
2025-07-29 07:00U:INCYNews ReleaseIncyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs
2025-07-24 17:02U:INCYNews ReleaseIncyte To Present Initial Data for its TGFbetaR2*PD-1-directed Bispecific Antibody (INCA33890) and its Selective Inhibitor of G12D-mutated KRAS (INCB161734) at the European Society of Medical Oncology (ESMO) Congress 2025
2025-07-10 08:00U:INCYNews ReleaseIncyte to Report Second Quarter Financial Results
2025-07-02 16:30U:INCYNews ReleaseIncyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
2025-06-26 07:30U:INCYNews ReleaseIncyte Appoints Bill Meury Chief Executive Officer; Herve Hoppenot to Retire
2025-06-20 16:30U:INCYNews ReleaseUpdate on FDA Review of Ruxolitinib Cream (Opzelura(TM)) for Children Ages 2-11 with Atopic Dermatitis
2025-06-18 15:39U:INCYNews ReleaseIncyte Announces FDA Approval of Monjuvi(TM) (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma
2025-06-15 04:00U:INCYNews ReleaseQIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)
2025-06-15 03:15U:INCYNews ReleasePositive Late-Breaking Data for Incyte's First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025
2025-06-12 18:45U:INCYNews ReleasePhase 3 Data for Incyte's Retifanlimab (Zynyz(TM)) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet